[1].Kleinberg TT, Tzekov RT, Stein L, Ravi N, Kaushal S. Vitreous substitutes: a comprehensive review[J]. Surv Ophthalmol. 2011;56(4):300–323.
[2].Shah NS, Beebe DC, Lake SP, Filas BA. On the Spatiotemporal Material Anisotropy of the Vitreous Body in Tension and Compression[J]. Ann Biomed Eng. 2016;44(10):3084–3095.
[3].Swann DA. Chemistry and biology of the vitreous body[J]. Int Rev Exp Pathol. 1980;22:1–64.
[4].Uji A, Yoshimura N. Microarchitecture of the Vitreous Body: A High-Resolution Optical Coherence Tomography Study[J]. Am J Ophthalmol. 2016;168:24–30.
[5].Mariacher S, Szurman P. [Artificial vitreous body: Strategies for vitreous body substitutes][J]. Ophthalmologe. 2015;112(7):572–579.
[6].Donati S, Caprani SM, Airaghi G, et al. Vitreous substitutes: the present and the future[J]. Biomed Res Int. 2014;2014:351804.
[7].Januschowski K, Seuthe AM, Boden KT, Spitzer MS, Szurman P. [Novel vitreous body replacement with hydrogel?][J]. Ophthalmologe. 2018;115(8):692–696.
[8].Deuchler S, Ackermann H, Singh P, Kohnen T, Wagner C, Koch F. Key Factors to Improve the Outcome of Retinal Reattachment Surgery in Proliferative Vitreoretinopathy and Proliferative Diabetic Retinopathy[J]. J Ophthalmol. 2017;2017:2323897.
[9].Durand ML. Bacterial and Fungal Endophthalmitis[J]. Clin Microbiol Rev. 2017;30(3):597–613.
[10].Khan MA, Brady CJ, Kaiser RS. Clinical management of proliferative vitreoretinopathy: an update[J]. Retina. 2015;35(2):165–175.
[11].Rejdak R, Juenemann AG, Natarajan S. Posterior Segment Ocular Trauma: Timing and Indications for Vitrectomy[J]. J Ophthalmol. 2017;2017:5250924.
[12].Gao QY, Fu Y, Hui YN. Vitreous substitutes: challenges and directions[J]. Int J Ophthalmol. 2015;8(3):437–440.
[13].Barth H, Crafoord S, Andreasson S, Ghosh F. A cross-linked hyaluronic acid hydrogel (Healaflow((R))) as a novel vitreous substitute[J]. Graefes Arch Clin Exp Ophthalmol. 2016;254(4):697–703.
[14].Alovisi C, Panico C, de Sanctis U, Eandi CM. Vitreous Substitutes: Old and New Materials in Vitreoretinal Surgery[J]. J Ophthalmol. 2017;2017:3172138.
[15].Biswas J, Verma A, Davda MD, Ahuja S, Pushparaj V. Intraocular tissue migration of silicone oil after silicone oil tamponade: a histopathological study of enucleated silicone oil-filled eyes[J]. Indian J Ophthalmol. 2008;56(5):425–428.
[16].Su X, Tan MJ, Li Z, et al. Recent Progress in Using Biomaterials as Vitreous Substitutes[J]. Biomacromolecules. 2015;16(10):3093–3102.
[17].Gao Q, Mou S, Ge J, et al. A new strategy to replace the natural vitreous by a novel capsular artificial vitreous body with pressure-control valve[J]. Eye (Lond). 2008;22(3):461–468.
[18].Lin X, Ge J, Gao Q, et al. Evaluation of the flexibility, efficacy, and safety of a foldable capsular vitreous body in the treatment of severe retinal detachment[J]. Invest Ophthalmol Vis Sci. 2011;52(1):374–381.
[19].Lin X, Wang Z, Jiang Z, et al. Preliminary efficacy and safety of a silicone oil-filled foldable capsular vitreous body in the treatment of severe retinal detachment[J]. Retina. 2012;32(4):729–741.
[20].Lin X, Sun X, Wang Z, et al. Three-Year Efficacy and Safety of a Silicone Oil-Filled Foldable-Capsular-Vitreous-Body in Three Cases of Severe Retinal Detachment[J]. Transl Vis Sci Technol. 2016;5(1):2.
[21].Chen H, Feng S, Liu Y, et al. Functional evaluation of a novel vitreous substitute using polyethylene glycol sols injected into a foldable capsular vitreous body[J]. J Biomed Mater Res A. 2013;101(9):2538–2547.
[22].Liu Y, Ke Q, Chen J, et al. Sustained mechanical release of dexamethasone sodium phosphate from a foldable capsular vitreous body[J]. Invest Ophthalmol Vis Sci. 2010;51(3):1636–1642.
[23].Wang P, Gao Q, Jiang Z, et al. Biocompatibility and retinal support of a foldable capsular vitreous body injected with saline or silicone oil implanted in rabbit eyes[J]. Clin Exp Ophthalmol. 2012;40(1):e67–75.
[24].Yang W, Yuan Y, Zong Y, et al. Preliminary study on retinal vascular and oxygen-related changes after long-term silicone oil and foldable capsular vitreous body tamponade[J]. Sci Rep. 2014;4:5272.
[25].Zhang R, Wang T, Xie C, et al. Evaluation of supporting role of a foldable capsular vitreous body with magnetic resonance imaging in the treatment of severe retinal detachment in human eyes[J]. Eye (Lond). 2011;25(6):794–802.
[26].Chan YK, Czanner G, Shum HC, Williams RL, Cheung N, Wong D. Towards better characterization and quantification of emulsification of silicone oil in vitro[J]. Acta Ophthalmol. 2017;95(5):e385-e392.
[27].Barca F, Caporossi T, Rizzo S. Silicone oil: different physical proprieties and clinical applications[J]. Biomed Res Int. 2014;2014:502143.
[28].Liu Z, Fu G, Liu A. The relationship between inflammatory mediator expression in the aqueous humor and secondary glaucoma incidence after silicone oil tamponade[J]. Exp Ther Med. 2017;14(6):5833–5836.
[29].Langham ME. Aqueous humor and control of intra-ocular pressure[J]. Physiol Rev. 1958;38(2):215–242.
[30].Roy Chowdhury U, Hann CR, Stamer WD, Fautsch MP. Aqueous humor outflow: dynamics and disease[J]. Invest Ophthalmol Vis Sci. 2015;56(5):2993–3003.
[31].Liu Y, Jiang Z, Gao Q, et al. Technical standards of a foldable capsular vitreous body in terms of mechanical, optical, and biocompatible properties[J]. Artif Organs. 2010;34(10):836–845.
[32].Chen J, Gao Q, Liu Y, et al. Clinical device-related article evaluation of morphology and functions of a foldable capsular vitreous body in the rabbit eye[J]. J Biomed Mater Res B Appl Biomater. 2011;97(2):396–404.
[33].Jiang Z, Wang P, Pan B, et al. Evaluation of levofloxacin release characteristics from a human foldable capsular vitreous body in vitro[J]. J Ocul Pharmacol Ther. 2012;28(1):33–40.
[34].Jiang Z, Wang T, Pan B, et al. Evaluation of the levofloxacin release characters from a rabbit foldable capsular vitreous body[J]. Int J Nanomedicine. 2012;7:1–10.
[35].Yan YN, Tian B, Liu Q, Wei WB. [Evaluation of the efficacy and safety of a foldable capsular vitreous body in the treatment of severe retinal detachment][J]. Zhonghua Yan Ke Za Zhi. 2019;55(4):259–266.
[36].Zheng H, Wang Z, Wang P, Liu Y, Jiang Z, Gao Q. Evaluation of 5-fluorouracil released from a foldable capsular vitreous body in vitro and in vivo[J]. Graefes Arch Clin Exp Ophthalmol. 2012;250(5):751–759.
[37].Wang T, Huang X, Gao Q, et al. A preliminary study to treat severe endophthalmitis via a foldable capsular vitreous body with sustained levofloxacin release in rabbits[J]. Invest Ophthalmol Vis Sci. 2013;54(1):804–812.
[38].Chen X, Liu Y, Jiang Z, Zhou L, Ge J, Gao Q. Protein kinase Calpha downregulation via siRNA-PKCalpha released from foldable capsular vitreous body in cultured human retinal pigment epithelium cells[J]. Int J Nanomedicine. 2011;6:1303–1311.